Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Pyruvate Nasal Spray for COVID-19
NCT04824365Phase 3Completed
- Sponsor
- Cellular Sciences
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium pyruvate nasal spray in coronavirus disease 2019 (COVID-19), sponsored by Cellular Sciences. Started Apr 2021; status: completed.
02
Drugs
sodium pyruvate nasal spray
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04824365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824365.